Acro Biomedical (ACBM) Cost of Revenue (2017 - 2022)

Acro Biomedical's Cost of Revenue history runs 6 years deep, the most recent figure standing at $296000.0 for Q4 2022.

• In Q4 2022, Cost of Revenue fell 33.93% year-over-year to $296000.0; the TTM figure through Sep 2023 stood at $296000.0 (down 55.82% YoY), while the FY2022 annual figure was $518000.0, down 44.78% from the prior year.
• Cost of Revenue was $296000.0 for Q4 2022 at Acro Biomedical, up from $222000.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $2.2 million in Q3 2018 to a low of $70000.0 in Q1 2021.
• Historically, Cost of Revenue has averaged $842290.9 across 5 years, with a median of $448000.0 in 2021.
• The sharpest annual moves came in 2021 and 2022: Cost of Revenue slumped 86.76% in 2021, then soared 217.14% in 2022.
• A 5-year view of Cost of Revenue shows it stood at $1.2 million in 2018, then slumped by 85.11% to $181440.0 in 2019, then jumped by 191.31% to $528560.0 in 2020, then decreased by 15.24% to $448000.0 in 2021, then slumped by 33.93% to $296000.0 in 2022.
• The last three Cost of Revenue figures came in at $296000.0 (Q4 2022), $222000.0 (Q1 2022), and $448000.0 (Q4 2021), per Business Quant data.